ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
Published 2 years ago • 227 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
0:26
acalabrutinib plus venetoclax and rituximab in the treatment of mcl
-
3:42
acalabrutinib plus venetoclax and rituximab in mcl & the importance of chemotherapy-free regimens
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:37
causes & management of ibrutinib discontinuation in cll
-
3:37
sympatico: ibrutinib combined with venetoclax in patients with r/r mcl
-
2:46
optimizing the combination of ibrutinib plus venetoclax in cll
-
1:44
triangle: ibrutinib with soc or as a substitute to autologous transplantation in first-line mcl
-
24:54
non-hodgkin lymphoma survivor story: mantle cell lymphoma | shari's story, part 1 (diagnosis)
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
9:02
martin dreyling, md: efficacy of first-line ibrutinib in mcl
-
1:55
ibrutinib in combination with rituximab – the future of treating fl
-
1:13
rationale for combining ibrutinib with tisa-cel in mcl
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
2:29
ibrutinib maintenance in mcl
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:01
next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:07
real-world evidence of venetoclax vs ibrutinib vs idelalisib
-
1:33
understanding the mechanisms of venetoclax and ibrutinib resistance
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation